EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets

Jie Xia, Siqin Li, Suling Liu, Lixing Zhang

MedComm · 2023-02 · 4 (1)

DOI: 10.1002/mco2.195 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 16.01.2023. Verfasst von Jie Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, Cancer Institutes, Key Labo…. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 303 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China, Program of Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The family of aldehyde dehydrogenases (ALDHs) contains 19 isozymes and is involved in the oxidation of endogenous and exogenous aldehydes to carboxylic acids, which contributes to cellular and tissue homeostasis. ALDHs play essential parts in detoxification, biosynthesis, and antioxidants, which are of important value for cell proliferation, differentiation, and survival in normal body tissues. However, ALDHs are frequently dysregulated and associated with various diseases like Alzheimer's disease, Parkinson's disease, and especially solid tumors. Notably, the involvement of the ALDHs in tumor progression is responsible for the maintenance of the stem‐cell‐like phenotype, triggering rapid and aggressive clinical progressions. ALDHs have captured increasing attention as biomarkers for disease diagnosis and prognosis. Nevertheless, these require further longitudinal clinical studies in large populations for broad application. This review summarizes our current knowledge regarding ALDHs as potential biomarkers in tumors and several non‐tumor diseases, as well as recent advances in our understanding of the functions and underlying molecular mechanisms of ALDHs in disease development. Finally, we discuss the therapeutic potential of ALDHs in diseases, especially in tumor therapy with an emphasis on their clinical implications.

Schlagwörter

Stichwörter der Autor:innen

aldehyde dehydrogenasebiomarkercancer stem celldiseasesolid tumortherapeutic resistance

Autor:innen und Institutionen

  • Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, Cancer Institutes, Key Laboratory of Breast Cancer in Shanghai, The Shanghai Key Laboratory of Me…
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing China.

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Xia, J., Li, S., Liu, S., & Zhang, L. (2023). Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets. MedComm, 4(1). https://doi.org/10.1002/mco2.195

Vancouver

Xia J, Li S, Liu S, Zhang L. Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets. MedComm. 2023;4(1). doi:10.1002/mco2.195

BibTeX
@article{Xia2023,
  author = {Xia, Jie and Li, Siqin and Liu, Suling and Zhang, Lixing},
  title = {Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets},
  journal = {MedComm},
  year = {2023},
  volume = {4},
  number = {1},
  doi = {10.1002/mco2.195}
}
Kostenlos starten →